トポテカン塩酸塩
トポテカン塩酸塩 物理性質(zhì)
- 融點(diǎn) :
- 213-218°C
- 貯蔵溫度 :
- Sealed in dry,Room Temperature
- 溶解性:
- DMSO（微量）、メタノール（微量）、水（微量）
- 外見 :
- 薄黃色から緑がかった粉末。
- 色:
- ホワイトからオフホワイト
- 安定性：:
- 吸濕性
- InChIKey:
- DGHHQBMTXTWTJV-UUTVKYGWNA-N
- SMILES:
- C12C=C3N(CC4C=C5C(CN(C)C)=C(O)C=CC5=NC3=4)C(=O)C=1COC(=O)[C@]2(O)CC.Cl |&1:27,r|
- CAS データベース:
- 119413-54-6(CAS DataBase Reference)
安全性情報(bào)
- リスクと安全性に関する聲明
- 危険有害性情報(bào)のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
|
| 危険有害性情報(bào) |
| コード |
危険有害性情報(bào) |
危険有害性クラス |
區(qū)分 |
注意喚起語 |
シンボル |
P コード |
| H340 |
遺伝性疾患のおそれ |
生殖細(xì)胞変異原性 |
1A, 1B |
危険 |
|
|
| H351 |
発がんのおそれの疑い |
発がん性 |
2 |
警告 |
|
P201, P202, P281, P308+P313, P405,P501 |
| H361 |
生殖能または胎児への悪影響のおそれの疑い |
生殖毒性 |
2 |
警告 |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| 注意書き |
| P201 |
使用前に取扱説明書を入手すること。 |
| P202 |
全ての安全注意を読み理解するまで取り扱わないこ と。 |
| P281 |
指定された個(gè)人用保護(hù)具を使用すること。 |
| P308+P313 |
暴露または暴露の懸念がある場(chǎng)合：醫(yī)師の診斷/手當(dāng)てを 受けること。 |
| P405 |
施錠して保管すること。 |
| P501 |
內(nèi)容物/容器を．．．に廃棄すること。 |
|
| メーカー |
製品番號(hào) |
製品説明 |
CAS番號(hào) |
包裝 |
価格 |
更新時(shí)間 |
購入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01CAY14129 |
Topotecan (hydrochloride) |
119413-54-6 |
5mg |
￥8700 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01CAY14129 |
Topotecan (hydrochloride) |
119413-54-6 |
10mg |
￥12000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01LKTT5761 |
トポテカン
Topotecan |
119413-54-6 |
1mg |
￥11800 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01TOC4562 |
トポテカン塩酸塩
Topotecan hydrochloride |
119413-54-6 |
10mg |
￥23000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01LKTT5761 |
トポテカン
Topotecan |
119413-54-6 |
5mg |
￥17800 |
2024-03-01 |
購入 |
トポテカン塩酸塩 化學(xué)特性,用途語,生産方法
効能
抗悪性腫瘍薬, トポイソメラーゼI阻害薬
商品名
ハイカムチン (日本化薬)
化學(xué)的特性
White Crystalline Solid
使用
A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic. Topotecan hydrochloride is a chemotherapy agent that is a topoisomerase 1 inhibitor.
一般的な説明
Topotecan is supplied in 4-mg vials and administered IV forthe treatment of ovarian cancer, cervical cancer, and smallcell lung cancer in those patients who did not respond tofirst-line therapy. Following IV administration, the drug iswidely distributed with 10% to 35% of the agent bound toplasma proteins. There is evidence that the agent may crossthe blood-brain barrier to some extent. In plasma, an equilibriumis established between the lactone and the less activehydroxy acid with 20% of the drug present as the lactone 1hour after the infusion is complete. In contrast to irinotecan,both the lactone and the hydroxy acid bind equally well tohuman serum albumin. N-Demethylation of the tertiaryamine to give the secondary amine is mediated by CYP3A4and represents a minor route of metabolism. Glucuronidationof the parent and the phase I metabolites also occurs to a limited(10%) extent.Elimination occurs primarily in theurine, with 30% of the dose being recovered as unchangeddrug. The terminal elimination half-life is 2 to 3 hours. Themajor toxicity seen for topotecan is dose-limiting myelosuppression.Nausea and vomiting are seen in most (70%–80%)patients, along with diarrhea and abdominal pain. Other toxicitiesinclude headache myalgias, alopecia and elevation ofserum transaminases, alkaline phosphatases, and bilirubin.Microscopic hematuria (blood in the urine) may also be seen.
薬物動(dòng)態(tài)學(xué)
Topotecan elimination is biphasic, with a terminal half-life of 2.0 to 3.5 hours. Lactone hydrolysis is rapid, and binding to serum proteins is limited to between 25 and 40%. CYP3A4-mediated N-dealkylation to monoand didealkylated metabolites occurs to a limited extent, and the O-glucuronides that form at multiple points along the metabolic path are excreted via the kidney.
臨床応用
This active camptothecin analogue is used by the IV route in the treatment of ovarian and small cell lung cancer that has not responded to first-line therapy.
トポテカン塩酸塩 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品
トポテカン塩酸塩 生産企業(yè)
Global( 522)Suppliers
119413-54-6(トポテカン塩酸塩)キーワード:
- 119413-54-6
- 1,4-di(4-benzhydryloxy-2-butynyl)piperazine
- 1,4-di(4-benzyloxy-2-butynyl)piperazine
- (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-(H-Pyrano[3' , 4':6,7]indolizino[1,2-b]quinoline-3,14[4H,12H]-dione monohydrochloride
- Topotecan Hydrochloride（TPT）
- S-(6-thioxo-1,6-dihydro-pyrimidin-4-yl)-isothiourea
- Topotecan hydrochloride(NSC-609699)
- Topotecan, Hydrochloride Salt
- Toputecan hydrochloride
- 2-Methyl-4-piperidino-butan-2-ol
- Topotecan HCl (HycaMtin)
- 3-Methoxy-5-Methyl-4-MethylaMino-heptanoic acid tert-butyl ester
- Nogitecan hydrochloride
- Topotecan hydrochloride
- (S)-10-((diMethylaMino)Methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride
- 2-Aza-bicyclo[4.1.0]heptane(HCl):2-Aza-bicyclo[4.1.0]heptane
- (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, hydrochloride (1:1)
- Nogitecan HCl
- Topotecan Hydrochloride Labeled d6
- Topotecan hydrochloride, >=99%
- N-(oxolan-2-ylmethyl)-2-(propan-2-ylamino)acetamide
- 2-[5-(1-ethylpyrazol-4-yl)-1,3,4-oxadiazol-2-yl]ethanamine
- (1S,5R)-3,3-difluoro-8-azabicyclo[3.2.1]octane
- 5-ALA HCl-13C
- 5-Amino-4-oxopentanoic Acid-13C
- 5-Aminolevulinic Acid-3-13C Hydrochloride
- Aminolevulinic-13C Acid Hydrochloride
- d-Aminolevulinic-13C Acid Hydrochloride
- Levulan-13C
- 9-[(DIMETHYLAMINO)METHYL]-10-HYDROXY-(20S)-CAMPTOTHECIN, HCL
- (4S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4',6-7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONE
- トポテカン塩酸塩
- ノギテカン塩酸塩
- ノギテカン塩酸塩 (JAN)
- ハイカムチン
- ノギテカン?塩酸塩
- 塩酸ノギテカン
- トポテカン?塩酸塩